2016: Drug Approvals Slowed to a Crawl
No matter what you think about the year 2016, one thing is for certain: many of us are glad it’s over. Although the political scene was a fast-paced frenzy, the FDA slowed down novel drug approvals to a crawl in the year past.
Novel therapeutic agents -- innovative products that meet an unmet medical need or advance public health care in a significant way -- continue to hit the market, and 2016 was no exception. However, the FDA approved only 22 novel drugs in 2016, shrinking from a record approval of 45 novel drugs in 2015 and 41 drugs in 2014. Here’s our quick review of the top new approvals of 2016, including many novel drugs, and a sneak peek of possibilities on tap for 2017.
More Hepatitis C Breakthroughs
Hepatitis C virus (HCV) affects over 3 million Americans and can lead to liver impairment, cirrhosis or even liver failure. HCV treatments continue to make headway in covering multiple genotypes in 2016.
- epatier (elbasvir and grazoprevir) from Merck, January 2016
- Epclusa (sofosbuvir and velpatasvir) from Gilead, June 2016
Thank you for submitting your comment!
no comments yet